Exploring the anti-Helicobacter pylori activity and mechanism of Shouhui Tongbian through chemical composition analysis and network pharmacology.

Shouhui Tongbian capsule (SHTB), a commercial Chinese patent medicine, has been shown to modulate gut microbiota dysbiosis and contains antibacterial active ingredients against Helicobacter pylori (H. pylori). H. pylori is a Gram-negative bacterium that colonizes the gastric mucosal and disrupt gast...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Ethnopharmacology Vol. 356
Autores principales: Zhang, Tianyi, Li, Hui, Hao, Yajie, Wang, Yanshun, Zhu, Zhixiang, Wang, Hui, He, Xiaozhong, Shi, Xiaoyan, Sun, Shaoming, Zhang, Guimin, Wei, Ruixia, Feng, Zhong
Formato: research Journal Article
Publicado: Elsevier B.V. Feb2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=189479087&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 189479087
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        03788741
        3MS
      jtl: Journal of Ethnopharmacology
      issn: 03788741
      maglogo: N
    pubinfo:
      dt: Feb2026
      vid: 356
      pid: 1004
      pub: Elsevier B.V.
    artinfo:
      ui:
        189479087
        189479087
        189479087
        10.1016/j.jep.2025.120869
        189479087
      ppct: 1
      formats:
      tig:
        atl: Exploring the anti-Helicobacter pylori activity and mechanism of Shouhui Tongbian through chemical composition analysis and network pharmacology.
      aug:
        au:
          Zhang, Tianyi
          Li, Hui
          Hao, Yajie
          Wang, Yanshun
          Zhu, Zhixiang
          Wang, Hui
          He, Xiaozhong
          Shi, Xiaoyan
          Sun, Shaoming
          Zhang, Guimin
          Wei, Ruixia
          Feng, Zhong
        affil: Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
      sug:
        subj:
          Medicine, Chinese Traditional
          Drugs, Chinese Herbal
          Gut Microbiota
          Antibiotics Therapeutic Use
          Antibiotics Pharmacodynamics
          Helicobacter Infections Drug Therapy
          Helicobacter Pylori Drug Effects
          Plant Extracts Pharmacodynamics
          Human
          In Vitro Studies
          Chromatography, High Pressure Liquid
          Mass Spectrometry
          Network Pharmacology
          Helicobacter Infections Microbiology
          Microbial Culture and Sensitivity Tests
          Microscopy, Electron
          Reverse Transcriptase Polymerase Chain Reaction
          Fluorescent Antibody Technique
          Staining and Labeling
          Blotting, Western
          Serologic Tests
          Urease Drug Effects
          Gene Expression
          NF-kappa B
          Mitogen-Activated Protein Kinases
          Intracellular Signaling Peptides and Proteins
          Amoxicillin
          Clarithromycin
          Ofloxacin
          Metronidazole
          Oncogenes
      ab: Shouhui Tongbian capsule (SHTB), a commercial Chinese patent medicine, has been shown to modulate gut microbiota dysbiosis and contains antibacterial active ingredients against Helicobacter pylori (H. pylori). H. pylori is a Gram-negative bacterium that colonizes the gastric mucosal and disrupt gastrointestinal microbiota balances. However, the precise mechanism underlying the anti- H. pylori effects of SHTB remains unclear. To investigate the in vitro anti- H. pylori effects and underlying mechanisms of SHTB. High-performance liquid chromatography (HPLC), ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), and network pharmacology analyses were used to identify the active compounds and potential targets of SHTB associated with H. pylori infection. The anti- H. pylori activity of SHTB was determined using the broth dilution method. Mechanistic studies were conducted through techniques such as electron microscopy observation, immunofluorescence staining, real-time quantitative polymerase chain reaction (RT-qPCR), and Western blotting analyses. A total of 42 compounds were identified in SHTB. Database screening yielded 365 target genes related to SHTB constituents and 1035 genes associated with H. pylori infection. In vitro assays demonstrated that the minimum inhibitory concentration (MIC) of SHTB against both susceptible and resistant H. pylori strains ranged from 160 to 320 μg/mL, with the minimum bactericidal concentration (MBC) being twice the MIC. No antagonistic effects were observed when SHTB was combined with clarithromycin, metronidazole, levofloxacin, or amoxicillin. SHTB disrupted H. pylori morphology, reduced urease activity, and downregulated virulence-associated gene expression. Cellular assay further indicated that SHTB enhanced the anti-adhesion capability of host cells. Furthermore, SHTB alleviated H. pylori infection-induced damage by inhibiting the abnormal activation of the PI3K/AKT, MAPK, and NF-κB signaling pathway. These findings provide a theoretical basis for elucidating the mechanism of SHTB against H. pylori infection and confirm its protective role in combating H. pylori infection through the regulation of the PI3K/AKT, MAPK, and NF-κB signaling pathway network. [Display omitted] • The SHTB exhibited anti- H. pylori activity. • Compared to eight single-herb drugs, SHTB exhibited superior anti- H. pylori activity. • SHTB inhibits the MAPK, PI3K/AKT, and NF-κB signaling pathways.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N